Navigation Links
REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
Date:1/17/2012

MOUNTAIN VIEW, Calif., Jan. 17, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the REVIVE study were published in The Journal of Sexual Medicine (JSM), a peer-reviewed journal with broad, multidisciplinary readership. REVIVE (TA-301) was a randomized, placebo-controlled, phase 3 study evaluating the safety and efficacy of avanafil, an investigational drug currently under review by the Food and Drug Administration (FDA) for the treatment of erectile dysfunction (ED).  In addition to significant improvements in erectile function and low rates of side effects common to phosphodiesterase type 5  inhibitors, the study also found that patients who attempted intercourse within 15 minutes of dosing were successful 64%, 67% and 71% of the time with 50, 100 and 200mg of avanafil treatment, respectively, versus 27% for placebo (p < 0.0001). The data suggest that avanafil may provide a rapid-onset, well-tolerated and effective treatment option for erectile dysfunction.

"While PDE-5 inhibitors are currently used as first-line therapy for treatment of ED in the general population, what's new and novel about avanafil is that it has a fast onset of action and high selectivity," said lead Investigator Irwin Goldstein, MD, Director of San Diego Sexual Medicine at Alvarado Hospital. "For patients, this means that avanafil, if approved, could be taken on-demand with potentially fewer side effects." 

An overview of the results as published in JSM is as follows:

  • Following 12 weeks of treatment, without restrictions on food or alcohol, all three doses of avanafil (50mg, 100mg and 200mg) were significantly superior to placebo for all primary endpoints (p </= 0.001). 
  • A secondary analysis using Sexual Encounter Profile, question 3 (SEP 3) to ev
    '/>"/>

SOURCE VIVUS
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE)
2. Secret of sandcastle construction could help revive ancient building technique, researchers say
3. Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures
4. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
5. NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011
6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
7. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
8. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
11. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... six-month periods ended June 30, 2015. Biorem,s complete second quarter financial ... FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , ... 2014 , 2015 , 2014 Revenue , ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... , Aug. 27, 2015 In response ... FedEx, UPS and The US Postal Service to ... classified as ,select agents, by the CDC, Marken ... handling these sensitive shipments. Marken uses ... regulations, trained and certified personnel to ensure the ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, ... the development and manufacture of highly valued cardiac markers used in early detection ... expertise with protein chemistry has led to the development and commercialization of important ...
(Date:8/26/2015)... China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has been informed that Magnum Opus ... by Mr. Yuen Kam, chairman of the board of ... (the "Shares") of  Excellent China Healthcare Investment Limited ("KKR ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... at, http://www.StopAfib.org, announces that September is Atrial Fibrillation,Month ... afib or AF., Once considered benign, this common ... stroke. Every five minutes, someone in the,U.S. has a ... and the #1 cause of,permanent disability, and takes a ...
... ... 2 -, BRISBANE, Calif., Sept. 2 InterMune, Inc.,(Nasdaq: ... $15 million,development milestone under its development collaboration with Roche for,the ... as R7227 at Roche), currently in a Phase 1b clinical ...
... SAN MATEO, Calif., Sept. 2 NeurogesX, Inc.,(Nasdaq: ... developing and,commercializing novel pain management therapies, announced today ... scheduled to,present at the Morgan Stanley Global Healthcare ... 9, 2008. Mr. DiTonno and Stephen Ghiglieri,Chief Financial ...
Cached Biology Technology:Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3
(Date:8/6/2015)... and TELTOW, Germany , ... 2015 Siggraph Conference, SensoMotoric Instruments (SMI) shows ... reality , based on Epson,s Moverio BT-200 ... tracking platform. With this new solution, unprecedented quality and ... hands-free interaction with context-sensitive displays. For the first time, ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... traditional French and Lady Gaga,s sophisticated designs, manicured nails have ... just pretty when nails appeared on all fingers and ... led to the development of critical functions, including finger pads ... whether it,s a nail polish brush or remover to prepare ...
... of mammary gland biology are essential in the fight ... as an Experimental Model , this organ represents an ... processes that occur throughout the body. The branching morphogenesis ... pregnancy, for example, recapitulate steps that occur in many ...
... roads as weed highways, and chemical warfare between alien and native ... in NeoBiota a new open-access, peer-reviewed, rapid ... Pensoft Publishers continuing the former NeoBiota Proceedings ... Khn from the Helmholtz Centre for Environmental Research ...
Cached Biology News:Researchers discover oldest evidence of nails in modern primates 2Researchers discover oldest evidence of nails in modern primates 3Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 2Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 3
Request Info...
Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
Anti-human VEGFR-1/Flt-1, clone Flt-1/EWI, Monoclonal Antibody...
Request Info...
Biology Products: